GlassScriptPhysician profile
Devinderpal Singh Randhawa
NPI 1225072648
$4,478.36
in general payments reported to CMS, 2019-2025
48 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $83.23 · 2021: $555 · 2022: $1,832 · 2023: $334 · 2024: $832 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $539.66 | 2019-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $334.87 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $273.13 | 2019-2025 | Keytruda, Keytruda Qlex |
| Astellas Pharma US INC | $268.47 | 2021-2022 | |
| Janssen Biotech, INC. | $267.72 | 2021-2025 | Rybrevant, Darzalex, Carvykti |
| Amgen INC. | $239.11 | 2019-2024 | |
| Celgene Corporation | $216.34 | 2021-2025 | Reblozyl |
| Eisai INC. | $201.75 | 2019-2024 | |
| Pfizer INC. | $190.52 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $170.02 | 2021-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $149.82 | 2022-2024 | Entyvio |
| Novartis Pharmaceuticals Corporation | $146.09 | 2019-2024 | |
| Genentech USA, INC. | $121.77 | 2019-2021 | |
| Ge Healthcare | $118.28 | 2021-2022 | |
| Gilead Sciences, INC. | $77.38 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devinderpal Randhawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.